<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285583</url>
  </required_header>
  <id_info>
    <org_study_id>WN29852</org_study_id>
    <secondary_id>TRO19622 CL E Q 1425-1</secondary_id>
    <nct_id>NCT01285583</nct_id>
  </id_info>
  <brief_title>Safety Extension Study of TRO19622 in ALS</brief_title>
  <official_title>An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to&#xD;
      riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the&#xD;
      preceding clinical trial (TRO19622 CL E Q 1015-1) in an open label extension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Entry of a patient into this safety study is intended to occur immediately after the patient&#xD;
      has finished participating in the preceding efficacy study (Protocol TRO19622 CL E Q 1015-1).&#xD;
&#xD;
      The Investigator will explain to the patients the nature of this open-label safety study, its&#xD;
      procedures, requirements and restrictions so as to obtain their written informed consent.&#xD;
&#xD;
      Each patient will be treated with olesoxime (TRO19622) until the results of the double-blind&#xD;
      trial become available with a maximum of 15 months.&#xD;
&#xD;
      Follow-up visits will take place every 3 months (+/- 2 weeks).&#xD;
&#xD;
      Safety assessments will be performed at all visits (every 3 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be the safety assessment.</measure>
    <time_frame>Safety assessment will be calculated from the date of enrollment for a maximum of 15 months.</time_frame>
    <description>safety criteria will be:&#xD;
Occurrence of AEs,&#xD;
Physical examination,&#xD;
Laboratory tests,&#xD;
Vital signs and ECG,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures</measure>
    <time_frame>Every 3 month, from the date of enrollment for a maximum of 15 months.</time_frame>
    <description>Secondary Outcome Measures will be:&#xD;
Survival time&#xD;
Total score of the 48-point ALS Functional Rating Scale Revised&#xD;
Slow Vital capacity (SVC) as a percentage of predicted SVC only if the SVC is performed by the site in a routine-way during standard ALS visit. This test will not be performed for the sole purpose of the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Olesoxime</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRO19622</intervention_name>
    <description>2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid</description>
    <arm_group_label>Olesoxime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have completed the 18-month safety and efficacy study of TRO19622 in&#xD;
             Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole (Protocol TRO19622&#xD;
             CL E Q 1015-1).&#xD;
&#xD;
          -  Both the investigator and the patient will decide based on previous good tolerance and&#xD;
             other clinical grounds whether or not to participate to the open-label extension.&#xD;
&#xD;
          -  If patients were on anti-vitamin K during the double-blind period, when entering the&#xD;
             open-label extension, coagulation tests should be monitored in exactly the same&#xD;
             conditions as if a new anticoagulant treatment was initiated and the dose of&#xD;
             anti-vitamin K should be adjusted accordingly.&#xD;
&#xD;
          -  Patients enrolling from this prior safety and efficacy study must:&#xD;
&#xD;
               -  If female of childbearing age of potential, continue to use adequate birth&#xD;
                  control methods and have a negative serum pregnancy test at the preceding&#xD;
                  double-blind protocol termination visit. Male and female partners must agree to&#xD;
                  use an effective method of birth control during their participation in the trial&#xD;
                  and for at least 15 days after the last IMP dose. Both partners must use reliable&#xD;
                  methods of contraception with 2 independent methods. The following measures are&#xD;
                  acceptable: Hormone contraceptives (e.g. oral contraceptives or comparable&#xD;
                  methods), intrauterine device, condoms with spermicidal coating or in combination&#xD;
                  with spermicidal creams, total abstinence or sterilisation performed in the past.&#xD;
&#xD;
               -  Be able to follow the investigator's instructions and be able to comply with the&#xD;
                  visit schedule and visit requirements; and&#xD;
&#xD;
               -  Sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients may not participate in this study if they have an ongoing, unresolved, clinically&#xD;
        significant medical problem (including patients having experienced serious adverse events&#xD;
        or non-serious, but medically significant adverse events during the preceding safety and&#xD;
        efficacy study that was assessed to be related to the study medication by the investigator)&#xD;
        that in the judgment of the investigator would make it unsafe for the patient to&#xD;
        participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Meininger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitie-Salpetriere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg - Dept Neurology - Herestraat 49</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre SLA Limoges - Service de Neurologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>D-30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry</name>
      <address>
        <city>London</city>
        <zip>SE58AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophoc Lateral Sclerosis</keyword>
  <keyword>TRO19622</keyword>
  <keyword>Olesoxime</keyword>
  <keyword>Trophos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

